Qualigen Therapeutics announces publication of key data in the peer-reviewed journal Molecules. The publication explained that the Company’s lead compound QN-302 had high anti-proliferative activity against pancreatic cancer cell lines, and anti-tumor activity in several in vivo models of the disease. The data also showed QN-302 causes downregulation of the expression of the S100P gene and the S100P protein in cells and in vivo. S100P is identified in connection with several human cancers and has been well documented as a potential biomarker specifically for pancreatic cancer. Tariq Arshad, M.D., M.B.A., the Company’s Chief Medical Officer and one of the publication authors stated, "This peer-reviewed publication provides exciting new data regarding the potential for S100P as a potential marker for therapeutic response in pancreatic cancer. This further validates the development of QN-302 and its potential to ultimately treat pancreatic cancer as well as other high unmet need malignancies. We are on track with executing all QN-302 IND-enabling studies toward submission of the IND application in the coming months and look forward to providing additional updates as they become available."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QLGN:
- Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
- Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
- Qualigen Therapeutics provides letter to shareholders
- Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
- Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302